Applied Biosystems to use device for strategic alliance

Applied Biosystems will use its Solid 3 System in a strategic alliance with TGen to research complex diseases and medical conditions, it has announced.

Under the collaboration, a team of scientists from both firms will use the next-generation genomic analysis platform to sequence DNA from thousands of sufferers of various illnesses.

It will enable investigators to use some of the best sequencing technology in order to focus on developing a more personalised approach to medicine, science sales specialists may want to note.

Mark Stevenson, president and chief operating officer at Life Technologies, noted the studies will allow clinicians to analyse and interpret genetic variation better in order to create more effective solutions.

He commented: "This strategic alliance will accelerate genomic discoveries by integrating relevant scientific findings into the clinical setting."

The division of Life Technologies, Applied Biosystems, provides innovative instrument systems to assist academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis.

Focusing on integrating medically directed technologies and applications into clinical practice, TGen asserts it is an emerging leader in the market.